Drug intelligence / Profile preview

AKIP1 siRNA

Development stage: Preclinical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

AKIP1 siRNA is a small interfering RNA designed to silence the expression of A-kinase-interacting protein 1 (AKIP1), an oncoprotein frequently upregulated in various cancers, including endometrial carcinoma and other gynecological malignancies. By utilizing the RNA interference (RNAi) pathway, AKIP1 siRNA targets and facilitates the degradation of AKIP1 mRNA, leading to a significant reduction in AKIP1 protein levels. Research indicates that AKIP1 promotes malignant cellular behaviors, tumor invasion, and resistance to chemotherapy. Silencing AKIP1 with siRNA has been shown in preclinical models to inhibit cell viability and enhance the chemosensitivity of cancer cells to agents such as cisplatin. It is currently utilized as a research tool to investigate the role of AKIP1 in cancer progression and as a potential therapeutic strategy to improve treatment outcomes in patients with high AKIP1 expression.

Other names: si-AKIP1si-AKIP-1si-AKIP 1AKIP1 small interfering RNAAKIP-1 small interfering RNAAKIP 1 small interfering RNAA-kinase-interacting protein 1 siRNA

Targets

AKIP1 (A-kinase-interacting protein 1)

Beyond the preview

Go deeper on AKIP1 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKIP1 siRNA.

Explore the full profile